Search Result

Results for "

trek1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Chloride Channel (2) Endogenous Metabolite (2) Isotope-Labeled Compounds (2) Potassium Channel (36) Reference Standards (7) Small Interfering RNA (siRNA) (3) Sodium Channel (8)
By Research Areas:	Cancer (6) Cardiovascular Disease (8) Inflammation/Immunology (3) Neurological Disease (33)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103371

DCPIB Maximum Cited Publications 11 Publications Verification	Chloride Channel Potassium Channel	Neurological Disease
DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels *TREK1* and TRAAK, and inhibits TRESK, *TASK1* and TASK3 (IC₅₀s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (I_Cl,swell), with an IC₅₀ of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels ^[1] .

HY-B0563

Ropivacaine 5+ Cited Publications	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese ^[1] . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management ^[1].

HY-B0563B

Ropivacaine hydrochloride 5+ Cited Publications	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese ^[1] . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo ^[1].

HY-104005

ML335 2 Publications Verification	Potassium Channel	Neurological Disease
ML335 is a selective activator of both *TREK-1* and *TREK-2*.

HY-B1500

2,2,2-Trichloroethanol 2 Publications Verification	Potassium Channel Endogenous Metabolite	Neurological Disease
2,2,2-Trichloroethanol, the active form of Chloral hydrate, is an agonist for the nonclassical K_2P channels TREK-1 (KCNK2) and TRAAK (KCNK4) ^[1].

HY-P3581

PE 22-28	Potassium Channel	Neurological Disease
PE 22-28 is a *TREK-1* inhibitor with IC₅₀ value of 0.12 nM. PE 22-28 also is a 7 amino-acid peptide that is used as a core sequence for preparing analogs by chemical modifications and also by substitution of amino-acids. PE 22-28 can be used for the research of depression ^[1].

HY-P1422

Spadin 1 Publications Verification	Potassium Channel 5-HT Receptor	Neurological Disease
Spadin, a natural peptide derived from a propeptide released in blood, is a potent TREK-1 channel blocker with IC₅₀ value of 10 nM. Spadin enhances dorsal raphe nucleus 5-HT neurotransmission in mice and induces hippocampal CREB activation and neurogenesis. Spadin can be used for antidepressant research ^[1] .

HY-B0563A

Ropivacaine hydrochloride monohydrate 5+ Cited Publications	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese ^[1] . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo ^[1].

HY-104027

ML402 1 Publications Verification	Potassium Channel	Neurological Disease
ML402, a thiophene-carboxamide, is a selective *K_2P2.1(TREK-1)* and *K_2P10.1(TREK-2)* activator. ML402 is inactive against K_2P4.1(TRAAK) ^[1].

HY-B0563S1

Ropivacaine-d7	Isotope-Labeled Compounds Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease
Ropivacaine-d₇ is deuterium labeled Ropivacaine. Ropivacain is a potent?sodium channel?blocker. Ropivacain blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese ^[1] . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain?management ^[1].

HY-108596

BL-1249	Potassium Channel	Inflammation/Immunology
BL-1249 is a nonsteroidal anti-inflammatory agent (NSAID) and a potassium channel activator. BL-1249 potently activates **K_2P2.1 (TREK-1) and K_2P10.1 (TREK-2) with EC₅₀ values of 5.5 μM and 8.0 μM, respectively. BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K_2P subfamilies. BL-1249 exhibits more selective for the bladder (EC₅₀ of 1.26 μM) than vascular tissue (EC₅₀** of 21.0 μM) ^[1] .

HY-W013712

GI-530159	Potassium Channel	Neurological Disease
GI-530159 is a selective opener of *TREK1* and *TREK2* potassium channels. GI-530159 displays selectivity for *TREK1/2* over TRAAK, TASK3 and other potassium channels, with an EC₅₀ of 0.76 μM for *TREK1*. GI-530159 reduces rat dorsal root ganglion neuron excitability and shows potential analgesic effect ^[1].

HY-137563

A2793	Potassium Channel	Neurological Disease
A2793 is an efficient dual TWIK-related acid-sensitive K ⁺ channel (TASK)-1/TRESK inhibitor, with an IC₅₀ of 6.8 μM for mTRESK. A2764 is more selective for TRESK, and it only moderately influences TREK-1 and TALK-1 ^[1].

HY-172182

ONO-2920632 VU6011887	Potassium Channel	Neurological Disease
ONO-2920632 is an orally active and central nervous system (CNS)-penetrant *TREK* activator, with EC₅₀ values of 0.3 µM and 2.8 μM for *TREK-1* and *TREK-2*, respectively. ONO-2920632 exhibits selectivity for other K2P channels (>91-fold selective versus TASK1, TASK2, TASK3, TRAAK, and TWIK2; 31-fold selective versus TRESK). ONO-2920632 possesses analgesic effects and can be used in research on pain, migraine, and neurological disorders.

HY-P1422A

Spadin TFA 1 Publications Verification	Potassium Channel 5-HT Receptor	Neurological Disease
Spadin TFA, a natural peptide derived from a propeptide released in blood, is a potent TREK-1 channel blocker with an IC₅₀ value of 10 nM. Spadin TFA enhances dorsal raphe nucleus 5-HT neurotransmission in mice and induces hippocampal CREB activation and neurogenesis. Spadin TFA can be used for antidepressant research ^[1] .

HY-135809

A2764 dihydrochloride	Potassium Channel	Neurological Disease
A2764 dihydrochloride is a highly selective inhibitor of TRESK (TWIK-related spinal cord K ⁺ channel, K2P18.1), which has moderate inhibitory effects on TREK-1 and TALK-1. A2764 dihydrochloride is more sensitive to the activated mTRESK channels (IC₅₀=6.8 μM) than the basal current. A2764 dihydrochloride can lead to cell depolarization and increased excitability in native cells, it has the potential for probing the role of TRESK channel in migraine and nociception ^[1].

HY-179004

ONO-9517601 VU6022856	Potassium Channel	Neurological Disease
ONO-9517601 is a potent, orally active, selective and CNS penetrant dual *TREK-1/TREK-2* inhibitor (TREK-1 IC₅₀= 0.067 μM, TREK-2 IC₅₀= 0.23 μM). ONO-9517601 displays robust efficacy in an MK-801 (HY-15084B) challenge rat novel object recognition (NOR) paradigm. ONO-9517601 can be used for research on neurological and cognitive disorders ^[1].

HY-134559

TKIM	Potassium Channel	Neurological Disease
TKIM is a TREK-1 channel inhibitor with an IC₅₀ of 2.96 μM. TKIM binds to the pocket of the intermediate (IM) state of TREK-1 ^[1].

HY-149536

*TWIK-1/TREK-1-IN-1*	Potassium Channel	Neurological Disease
TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC₅₀s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects ^[1].

HY-149538

*TWIK-1/TREK-1-IN-3*	Potassium Channel	Neurological Disease
TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC₅₀s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects ^[1].

HY-179005

ONO-7927846 VU6024391	Potassium Channel	Neurological Disease
ONO-7927846 is a potent, orally active, selective and CNS penetrant dual *TREK-1/TREK-2* inhibitor (TREK-1 IC₅₀= 0.11 μM, TREK-2 IC₅₀= 0.29 μM). ONO-7927846 displays robust efficacy in an MK-801 (HY-15084B) challenge rat novel object recognition (NOR) paradigm. ONO-7927846 can be used for research on neurological and cognitive disorders ^[1].

HY-149537

*TWIK-1/TREK-1-IN-2*	Potassium Channel	Neurological Disease
TWIK-1/TREK-1-IN-2 (Compound 2g) is a *TWIK-1/TREK-1* inhibitor. TWIK-1/TREK-1-IN-2 inhibits TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC₅₀s of 10.13 μM and 15.5 μM. TWIK-1/TREK-1-IN-2 is an antidepressant ^[1].

HY-160789

C3001a	Potassium Channel	Neurological Disease Inflammation/Immunology
C3001a is a selective *TREK-1* and TREK-2 channel activator with EC₅₀ values of 12.81 μM and 11.31 μM, respectively. C3001a does not affect other two-pore domain K ⁺ (K2P) channels. C3001a binds to the cryptic binding site formed by P1 and TM4 in TREK-1. C3001a can be used for the study of pain and pancreatitis ^[1].

HY-118628A

BML264 (E)-N-(p-Amylcinnamoyl) anthranilic acid	Potassium Channel	Cardiovascular Disease
BML264 ((E)-N-(p-amylcinnamoyl) anthranilic acid) is an agonist for *TREK-1*. BML264 can be used to study diseases associated with TASK1 dysfunction ^[1].

HY-178233

CAT335	Potassium Channel	Neurological Disease
CAT335 is a *TREK* activator. CAT335 selectively and irreversibly activates TREK-1 ^CG∗. CAT335 can be used in the research of pain sensation, sleep, and intraocular pressure ^[1].

HY-116704

11-Deoxyprostaglandin F2α	Potassium Channel	Neurological Disease
11-Deoxyprostaglandin F2α is an activator for *TREK-2* channels with EC₅₀ of 0.294 μM. 11-Deoxyprostaglandin F2α inhibits the K2P channel *TREK-1* ^[1].

HY-B1500R

2,2,2-Trichloroethanol (Standard)	Reference Standards Potassium Channel Endogenous Metabolite	Neurological Disease
2,2,2-Trichloroethanol (Standard) is the analytical standard of 2,2,2-Trichloroethanol. This product is intended for research and analytical applications. 2,2,2-Trichloroethanol, the active form of Chloral hydrate, is an agonist for the nonclassical K2P channels TREK-1 (KCNK2) and TRAAK (KCNK4) ^[1].

HY-B0563R

Ropivacaine (Standard)	Reference Standards Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine (Standard) is the analytical standard of Ropivacaine. This product is intended for research and analytical applications. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese ^[1] . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management ^[1].

HY-B0563AR

Ropivacaine hydrochloride monohydrate (Standard)	Reference Standards Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine (hydrochloride monohydrate) (Standard) is the analytical standard of Ropivacaine (hydrochloride monohydrate). This product is intended for research and analytical applications. Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese ^[1] . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo ^[1].

HY-B0563BS

Ropivacaine-d7 hydrochloride	Isotope-Labeled Compounds Potassium Channel Sodium Channel	Neurological Disease
Ropivacaine-d₇ hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) ^[1]. Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .

HY-172455

TREK inhibitor-3	Potassium Channel	Neurological Disease
TREK inhibitor-3 (Cpd8l) is a selective and BBB-permeable *TREK-1* inhibitor with an IC₅₀ of 0.81 μM. TREK inhibitor-3 has neuroprotective effects, which can significantly reduce the death of cortical neurons induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and improve brain injury in mice models of middle cerebral artery occlusion/reperfusion (MCAO/R). TREK inhibitor-3 can be used in the research of ischemic stroke ^[1].

HY-104005R

ML335 (Standard)	Reference Standards Potassium Channel	Neurological Disease
ML335 (Standard) is the analytical standard of ML335 (HY-104005). This product is intended for research and analytical applications. ML335 is a selective activator of both TREK-1 and TREK-2.

HY-RS07158

KCNK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KCNK2 Human Pre-designed siRNA Set A contains three designed siRNAs for KCNK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KCNK2 Human Pre-designed siRNA Set A KCNK2 Human Pre-designed siRNA Set A

HY-RS24544

Kcnk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Kcnk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Kcnk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kcnk2 Rat Pre-designed siRNA Set A Kcnk2 Rat Pre-designed siRNA Set A

HY-B0563C

Ropivacaine mesylate 5+ Cited Publications	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibressup>[1] . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel)?TREK-1?with an IC₅₀?of 402.7 μM in COS-7 cell's membrane .

HY-103371R

DCPIB (Standard)	Reference Standards Chloride Channel Potassium Channel	Neurological Disease
DCPIB (Standard) is the analytical standard of DCPIB (HY-103371). This product is intended for research and analytical applications. DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC₅₀s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC₅₀ of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels ^[1] .

HY-108596R

BL-1249 (Standard)	Reference Standards Potassium Channel	Inflammation/Immunology
BL-1249 (Standard) is the analytical standard of BL-1249 (HY-108596). This product is intended for research and analytical applications. BL-1249 is a nonsteroidal anti-inflammatory agent (NSAID) and a potassium channel activator. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC₅₀ values of 5.5 μM and 8.0 μM, respectively. BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K2P subfamilies. BL-1249 exhibits more selective for the bladder (EC₅₀ of 1.26 μM) than vascular tissue (EC₅₀ of 21.0 μM) ^[1] .

HY-RS18069

Kcnk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Kcnk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kcnk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kcnk2 Mouse Pre-designed siRNA Set A Kcnk2 Mouse Pre-designed siRNA Set A

HY-104027R

ML402 (Standard)	Reference Standards Potassium Channel	Neurological Disease
ML402 (Standard) is the analytical standard of ML402 (HY-104027). This product is intended for research and analytical applications. ML402, a thiophene-carboxamide, is a selective K2P2.1(TREK-1) and K2P10.1(TREK-2) activator. ML402 is inactive against K2P4.1(TRAAK) ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P3581

PE 22-28	Potassium Channel	Neurological Disease
PE 22-28 is a *TREK-1* inhibitor with IC₅₀ value of 0.12 nM. PE 22-28 also is a 7 amino-acid peptide that is used as a core sequence for preparing analogs by chemical modifications and also by substitution of amino-acids. PE 22-28 can be used for the research of depression ^[1].

HY-P1422

Spadin 1 Publications Verification	Potassium Channel 5-HT Receptor	Neurological Disease
Spadin, a natural peptide derived from a propeptide released in blood, is a potent TREK-1 channel blocker with IC₅₀ value of 10 nM. Spadin enhances dorsal raphe nucleus 5-HT neurotransmission in mice and induces hippocampal CREB activation and neurogenesis. Spadin can be used for antidepressant research ^[1] .

HY-P1422A

Spadin TFA 1 Publications Verification	Potassium Channel 5-HT Receptor	Neurological Disease
Spadin TFA, a natural peptide derived from a propeptide released in blood, is a potent TREK-1 channel blocker with an IC₅₀ value of 10 nM. Spadin TFA enhances dorsal raphe nucleus 5-HT neurotransmission in mice and induces hippocampal CREB activation and neurogenesis. Spadin TFA can be used for antidepressant research ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1500

2,2,2-Trichloroethanol 2 Publications Verification	Natural Products Endogenous metabolite Source Classification	Potassium Channel Endogenous Metabolite
2,2,2-Trichloroethanol, the active form of Chloral hydrate, is an agonist for the nonclassical K_2P channels TREK-1 (KCNK2) and TRAAK (KCNK4) ^[1].

HY-B1500R

2,2,2-Trichloroethanol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Potassium Channel Endogenous Metabolite
2,2,2-Trichloroethanol (Standard) is the analytical standard of 2,2,2-Trichloroethanol. This product is intended for research and analytical applications. 2,2,2-Trichloroethanol, the active form of Chloral hydrate, is an agonist for the nonclassical K2P channels TREK-1 (KCNK2) and TRAAK (KCNK4) ^[1].

Cat. No.	Product Name	Chemical Structure

HY-B0563S1

Ropivacaine-d7

Ropivacaine-d₇ is deuterium labeled Ropivacaine. Ropivacain is a potent?sodium channel?blocker. Ropivacain blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese ^[1] . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain?management ^[1].

HY-B0563BS

Ropivacaine-d7 hydrochloride

Ropivacaine-d₇ hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) ^[1]. Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks